David Gonzales

3.6k total citations · 1 hit paper
25 papers, 2.7k citations indexed

About

David Gonzales is a scholar working on Physiology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Gonzales has authored 25 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Physiology, 7 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Gonzales's work include Smoking Behavior and Cessation (16 papers), Nicotinic Acetylcholine Receptors Study (7 papers) and Asthma and respiratory diseases (5 papers). David Gonzales is often cited by papers focused on Smoking Behavior and Cessation (16 papers), Nicotinic Acetylcholine Receptors Study (7 papers) and Asthma and respiratory diseases (5 papers). David Gonzales collaborates with scholars based in United States, Canada and United Kingdom. David Gonzales's co-authors include Nancy A. Rigotti, Raymond Niaura, Michael J. Durcan, Joseph A. Johnston, David P.L. Sachs, Robert P. Murray, Richard F. Rakos, A. Sonia Buist, J. D. White and Troy D. Wolter and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

David Gonzales

25 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

2006 1.0k citations David Gonzales JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Gonzales United States	17	2.0k	900	552	509	462	25	2.7k
J. Taylor Hays United States	33	2.2k 1.1×	778 0.9×	404 0.7×	659 1.3×	617 1.3×	108	3.2k
David P.L. Sachs United States	22	1.9k 1.0×	961 1.1×	376 0.7×	640 1.3×	433 0.9×	60	2.9k
Moise Khayrallah United States	13	985 0.5×	563 0.6×	198 0.4×	256 0.5×	233 0.5×	15	2.1k
Penny N. Glover United States	10	930 0.5×	456 0.5×	181 0.3×	291 0.6×	202 0.4×	14	1.3k
K.O. Fagerström Sweden	11	1.1k 0.6×	312 0.3×	200 0.4×	334 0.7×	293 0.6×	17	1.4k
Carl R. Sullivan United States	9	749 0.4×	395 0.4×	168 0.3×	334 0.7×	191 0.4×	16	1.3k
Cristina Russ United States	17	1.2k 0.6×	431 0.5×	159 0.3×	327 0.6×	391 0.8×	56	1.8k
John R. Hughes United States	14	1.4k 0.7×	343 0.4×	73 0.1×	442 0.9×	543 1.2×	29	1.8k
Linda Hyder Ferry United States	17	808 0.4×	399 0.4×	93 0.2×	252 0.5×	117 0.3×	21	1.5k
Pamela Sullivan United States	4	657 0.3×	349 0.4×	159 0.3×	205 0.4×	134 0.3×	4	1.0k

Countries citing papers authored by David Gonzales

Since Specialization

Citations

This map shows the geographic impact of David Gonzales's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Gonzales with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Gonzales more than expected).

Fields of papers citing papers by David Gonzales

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Gonzales. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Gonzales. The network helps show where David Gonzales may publish in the future.

Co-authorship network of co-authors of David Gonzales

This figure shows the co-authorship network connecting the top 25 collaborators of David Gonzales. A scholar is included among the top collaborators of David Gonzales based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Gonzales. David Gonzales is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

McEvoy, Cindy T., Lyndsey E. Shorey‐Kendrick, Julia A. Harris, et al.. (2023). Effect of Vitamin C Supplementation for Pregnant Smokers on Offspring Airway Function and Wheeze at Age 5 Years: Follow-up of a Randomized Clinical Trial. Obstetrical & Gynecological Survey. 78(7). 387–389. 3 indexed citations

2.

Gonzales, David, et al.. (2020). Improving Smoking Cessation Outcomes Through Tailored-Risk Patient Messages at a University Hospital Tobacco Cessation Service. The Joint Commission Journal on Quality and Patient Safety. 46(5). 250–260. 3 indexed citations

3.

McEvoy, Cindy T., Lyndsey E. Shorey‐Kendrick, Diane Schilling, et al.. (2020). Vitamin C to pregnant smokers persistently improves infant airway function to 12 months of age: a randomised trial. European Respiratory Journal. 56(6). 1902208–1902208. 24 indexed citations

4.

Gonzales, David, et al.. (2016). Two Years in the Life of a University Hospital Tobacco Cessation Service: Recommendations for Improving the Quality of Referrals. The Joint Commission Journal on Quality and Patient Safety. 42(5). 209–AP3. 5 indexed citations

5.

Gonzales, David, et al.. (2014). Retreatment With Varenicline for Smoking Cessation in Smokers Who Have Previously Taken Varenicline: A Randomized, Placebo-Controlled Trial. Clinical Pharmacology & Therapeutics. 96(3). 390–396. 34 indexed citations

6.

McEvoy, Cindy T., Diane Schilling, Keith E. Jackson, et al.. (2014). Vitamin C Supplementation for Pregnant Smoking Women and Pulmonary Function in Their Newborn Infants. JAMA. 311(20). 2074–2074. 137 indexed citations

7.

Hatsukami, Dorothy K., Douglas E. Jorenby, David Gonzales, et al.. (2011). Immunogenicity and Smoking-Cessation Outcomes for a Novel Nicotine Immunotherapeutic. Clinical Pharmacology & Therapeutics. 89(3). 392–399. 144 indexed citations

8.

Gonzales, David, Douglas E. Jorenby, Thomas H. Brandon, Carmen Arteaga, & Theodore C. Lee. (2010). Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo. Addiction. 105(11). 2002–2013. 29 indexed citations

9.

Rigotti, Nancy A., David Gonzales, Lowell C. Dale, Daniel Lawrence, & Yuchiao Chang. (2009). A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction. 104(2). 266–276. 51 indexed citations

10.

Gonzales, David, et al.. (2007). Support for spirituality in smoking cessation: Results of pilot survey. Nicotine & Tobacco Research. 9(2). 299–303. 14 indexed citations

11.

Gonzales, David. (2006). Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA. 296(1). 47–47. 1038 indexed citations breakdown →

12.

Jorenby, Douglas E., Serena Tonstad, & David Gonzales. (2006). Efficacy of Varenicline for Smoking Cessation—Reply. JAMA. 296(21). 2555–2555. 1 indexed citations

13.

Durcan, Michael J., J. D. White, Joseph A. Johnston, et al.. (2002). The effect of bupropion sustained-release on cigarette craving after smoking cessation. Clinical Therapeutics. 24(4). 540–551. 72 indexed citations

14.

Hurt, R. Douglas, Troy D. Wolter, Nancy A. Rigotti, et al.. (2002). Bupropion for pharmacologic relapse prevention to smoking. Addictive Behaviors. 27(4). 493–507. 48 indexed citations

15.

Gonzales, David. (2002). Effects of gender on relapse prevention in smokers treated with bupropion SR. American Journal of Preventive Medicine. 22(4). 234–239. 76 indexed citations

16.

Hays, J. Taylor, R. Douglas Hurt, Nancy A. Rigotti, et al.. (2001). Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking Cessation. Annals of Internal Medicine. 70 indexed citations

17.

Tashkin, DP, Richard E. Kanner, William C. Bailey, et al.. (2001). Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. The Lancet. 357(9268). 1571–1575. 304 indexed citations

18.

Hays, J. Taylor, R. Douglas Hurt, Nancy A. Rigotti, et al.. (2001). Sustained-Release Bupropion for Pharmacologic Relapse Prevention after Smoking Cessation. Annals of Internal Medicine. 135(6). 423–433. 261 indexed citations

19.

Nides, Mitchell, Richard F. Rakos, David Gonzales, et al.. (1995). Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study.. Journal of Consulting and Clinical Psychology. 63(1). 60–69. 114 indexed citations

20.

Rakos, Richard F., et al.. (1995). Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study.. Journal of Consulting and Clinical Psychology. 63(1). 60–69. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact